25th Oct 2006 12:21
Henderson Morley PLC25 October 2006 25 OCTOBER 2006 HENDERSON MORLEY PLC (AIM) Business: Drug Discovery RESULT OF AGM AND AGM STATEMENT The Board of Henderson Morley Plc ("Henderson Morley" or "the Company") ispleased to announce that at the Company's AGM held earlier today, all theresolutions were duly passed. Executive Chairman Andrew Knight made the following comments: "Henderson Morleyhas had an extremely busy period and we look forward to pursuing furtheropportunities as we work towards the anticipated commercialization of our patentportfolio and continue to develop ICVT. To this end we were pleased to havesecured further funding earlier this month. "We continue to look for new commercial opportunities - a point highlighted bythe recent US and European licenses granted to Cutanea Life Sciences and AmistadPharma, which will help to underpin further development. "The Company has focused on the development of its technology portfolio andcontinues to seek new opportunities to grow its revenue streams both in the nearand long term by focusing on both human and animal health. I believe the Companyhas made excellent progress this year and look forward to updating the market onfurther developments in due course." ---ENDS--- ENQUIRIES: HENDERSON MORLEY PLC Tel: 0121 442 4600Andrew Knight, Chairman BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7430 1600Maxine Barnes Mobile: 07860 489571Nick Rome BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126Neil Baldwin Further information on Henderson Morley plc can be accessed through theCompany's website at www.henderson-morley.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
HML.L